In a 7-year follow-up from the PARTNER 3 trial, Dr. Martin B. Leon and colleagues revealed that transcatheter aortic-valve replacement (TAVR) using the SAPIEN 3 valve produced outcomes on par with surgical aortic-valve replacement in low-risk adults with severe aortic stenosis. Both methods had similar rates of mortality, stroke, and rehospitalization, with 73.4% of TAVR patients surviving without valve failure. Nonetheless, TAVR had lower instances of new-onset atrial fibrillation and had some differences in complication rates, indicating the need for careful patient selection.
1. PARTNER 3 trial showed TAVR outcomes comparable to surgical replacement. 2. 73.4% of TAVR patients alive without valve failure at 7 years. 3. Atrial fibrillation less common with TAVR (17.7%). 4. Surgical withdrawal from follow-up could affect mortality estimates. 5. Study funded by Edwards Lifesciences with authors reporting funding support. 6. Complications varied between procedures; mild paravalvular regurgitation was higher with TAVR. 7. Overall mortality rates similar between both groups.
Listen Tab content
